Last reviewed · How we verify
Crushed ticagrelor followed by morphine
Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis.
Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis. Used for Acute coronary syndrome with rapid antiplatelet and analgesic management, Acute myocardial infarction with pain control.
At a glance
| Generic name | Crushed ticagrelor followed by morphine |
|---|---|
| Also known as | Brilique |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Drug class | P2Y12 receptor antagonist + opioid analgesic |
| Target | P2Y12 receptor (ticagrelor); mu opioid receptor (morphine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a direct P2Y12 receptor antagonist that prevents adenosine diphosphate (ADP)-induced platelet activation and aggregation, reducing thrombotic events. Morphine is an opioid agonist that binds to mu receptors in the central nervous system to provide analgesia and anxiolysis. This combination is used in acute coronary syndromes to provide rapid antiplatelet effect (via crushed formulation for faster absorption) combined with pain management and sedation.
Approved indications
- Acute coronary syndrome with rapid antiplatelet and analgesic management
- Acute myocardial infarction with pain control
Common side effects
- Bleeding
- Bradycardia
- Respiratory depression
- Hypotension
- Nausea
Key clinical trials
- Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine (PHASE4)
- Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: